argenx SE
registrational study of bullous pemphigoid to start in and relapsing within paras | argenx SE
Company
Deck Type
Sector
Industry
Deck date
July 2021
Slide
45 of 69
Related slides by other companies
Theravance Biopharma
Investor Conference
November 2022
new study in patients with cypress | Theravance Biopharma
BioAtla
Investor Presentation
November 2022
ups part of the phase study potentially registrational | BioAtla
Other recent decks by argenx SE
See all presentations (28 decks)
Results
February 2024
Investor Conference
January 2024
Investor Presentation
December 2023
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights